Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Spyre Therapeutics (SYRE)
NASDAQ:SYRE
RESEARCH TOOLSreports
SYRE Stock Chart & Stats
Day’s Range― - ―
52-Week Range$20.07 - $47.97
Previous CloseN/A
Volume84.75K
Average Volume (3M)539.44K
Market Cap
$1.27B
Enterprise Value$1.24B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)2.3
Beta0.58
Next Earnings
Feb 27, 2025EPS Estimate
-1.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.21
Shares Outstanding58,706,220
10 Day Avg. Volume603,105
30 Day Avg. Volume539,440
Standard Deviation0.42
R-Squared0.13
Alpha-0.00864
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1253.85
Price to Cash Flow (P/CF)-9.40
P/FCF Ratio0.00
Enterprise Value/Market Cap0.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.88K
Enterprise Value/Ebitda-6.35
Forecast
1Y Price Target
$54.33Price Target Upside137.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
---
Spyre Therapeutics News
PremiumCompany Announcements
Spyre Therapeutics Faces Internal Control Challenges---
Bulls Say, Bears Say
Bulls Say
Market OpportunitiesSpyre's decision to pursue rheumatoid arthritis with its TL1A inhibitor could enable it to be first to market in this large indication, which is estimated to have significant sales potential.
Product DevelopmentTL1A inhibitors in late-stage clinical development for UC have not been associated with any significant safety concerns, suggesting potential for a cleaner safety profile compared to the TNF class.
Scientific ValidationMolecular targets of SPY001, SPY002, & SPY003 are clinically validated and relatively derisked.
Bears Say
Clinical Trial ProgressPh1 data on each asset would be needed before combo dosing can begin in Ph2, delaying potential benefits.
Development DelaysSuch data will likely not be at hand within the next 2 years, delaying potential valuation growth.
Valuation ConcernsLead opportunities appear priced in, limiting potential upside in monotherapy revenue.
---
Ownership Overview
9.92% Insiders
16.42% Mutual Funds
0.06% Other Institutional Investors
63.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
SYRE FAQ
What was Spyre Therapeutics’s price range in the past 12 months?
Spyre Therapeutics lowest stock price was $20.07 and its highest was $47.97 in the past 12 months.
What is Spyre Therapeutics’s market cap?
Spyre Therapeutics’s market cap is $1.27B.
When is Spyre Therapeutics’s upcoming earnings report date?
Spyre Therapeutics’s upcoming earnings report date is Feb 27, 2025 which is in 22 days.
How were Spyre Therapeutics’s earnings last quarter?
Spyre Therapeutics released its earnings results on Nov 07, 2024. The company reported -$1.36 earnings per share for the quarter, missing the consensus estimate of -$0.824 by -$0.536.
Is Spyre Therapeutics overvalued?
According to Wall Street analysts Spyre Therapeutics’s price is currently Undervalued.
Does Spyre Therapeutics pay dividends?
Spyre Therapeutics does not currently pay dividends.
What is Spyre Therapeutics’s EPS estimate?
Spyre Therapeutics’s EPS estimate is -1.01.
How many shares outstanding does Spyre Therapeutics have?
Spyre Therapeutics has 58,706,220 shares outstanding.
What happened to Spyre Therapeutics’s price movement after its last earnings report?
Spyre Therapeutics reported an EPS of -$1.36 in its last earnings report, missing expectations of -$0.824. Following the earnings report the stock price went up 5.015%.
Which hedge fund is a major shareholder of Spyre Therapeutics?
Currently, no hedge funds are holding shares in SYRE
---
Spyre Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.33 (137.25% Upside)
$54.33 (137.25% Upside)
Blogger Sentiment
Bullish
SYRE Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 822.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.70%
12-Months-Change
Fundamentals
Return on Equity
180.16%
Trailing 12-Months
Asset Growth
103.16%
Trailing 12-Months
Company Description
Spyre Therapeutics
Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.
---
SYRE Stock 12 Month Forecast
Average Price Target
$54.33
▲(137.25% Upside)
Technical Analysis
Best Analysts Covering SYRE
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+47.64%
reiterated a buy rating 23 days ago
Copying Alex Thompson CFA's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +47.64% per trade.
---